Search Results

December 9, 2022

Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

December 9, 2022

Real-World Study Confirms Benefit of XARELTO® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients

Head-to-head observational analysis showed XARELTO® as effective in treating cancer-associated thromboembolism (CAT) as apixaban Venous thromboembolism (VTE) is the second-leading cause of death in patients with cancer1

Global health equity

November 15, 2022

Johnson & Johnson Rises to #2 in Ranking of Companies’ Efforts to Expand Access to Medicines Worldwide

Innovative Medicine

November 11, 2022

New TREMFYA® (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term Efficacy And Sustained Achievement Among A Diverse Active Psoriatic Arthritis Patient Population

Early skin and enthesitis responses in active psoriatic arthritis patients treated with TREMFYA predicted long-term clinical response, measured at two years, including disease remission Bio-naïve, TREMFYA-treated patients maintained several disease control endpoints through two years, regardless of baseline characteristics or dosing regimen

Innovative Medicine

November 10, 2022

New TREMFYA® (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful Long-Term Improvement in Health-Related Quality of Life

Post-hoc analysis of DISCOVER-2 Phase 3 data suggest active psoriatic arthritis patients with week 8 response to TREMFYA showed meaningful improvements in health-related quality of life at week 100, compared to patients without early response Additional post-hoc analyses show treatment with TREMFYA demonstrated improvements of fatigue (FACIT-F scale) at week 8, demonstrating clinically meaningful and durable long-term improvements, with nearly a third maintaining normative levels through week 100

Innovative Medicine

November 7, 2022

Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension

Aprocitentan is an investigational antihypertensive drug with a novel mechanism of action

Innovative Medicine

November 4, 2022

Janssen’s Save Legs. Change Lives.™ is Creating a More Equitable Future for Communities at Risk of PAD-Related Amputations

Black Americans are up to four times more likely to have a PAD-related amputation,1 largely due to greater delays in care2 and less access to quality vascular care1 Save Legs. Change Lives.™ aims to reach more than 10 million Black Americans over the multi-year initiative

Innovative Medicine

November 3, 2022

Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio

More than 50 presentations across hematologic malignancies and diseases demonstrate Janssen’s commitment to innovation and transforming the treatment of blood cancers across lines of therapy and patient types

Innovative Medicine

October 24, 2022

New TREMFYA® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis

Previously reported results from QUASAR Induction Study 1 showed clinical response was achieved by approximately 60 percent of patients at week 12 Study results presented at 2022 American College of Gastroenterology Annual Meeting showed that continued treatment with subcutaneous TREMFYA allowed a mean of 52.1 percent of IV TREMFYA week 12 clinical nonresponders to achieve clinical response at week 24

Innovative Medicine

October 10, 2022

STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis

55.2 percent of induction responder patients treated with STELARA at the start of maintenance were in symptomatic remission approximately four years later (at week 200), 96.4 percent without corticosteroids Overall, 79.1 percent of patients treated with STELARA in the long-term extension (LTE) who were receiving corticosteroids at maintenance baseline were no longer receiving corticosteroids by week 200

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine